These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33372551)

  • 1. Questions and facts regarding denosumab discontinuation among postmenopausal women.
    Makras P; Anastasilakis AD
    Expert Opin Drug Saf; 2021 May; 20(5):499-501. PubMed ID: 33372551
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple severe vertebral fractures during the 3-month period following a missed dose of denosumab in a postmenopausal woman with osteoporosis previously treated with alendronate
.
    Bandeira F; Torres G; Bandeira E; Duarte MB; Nóbrega AM; Bandeira L
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):163-166. PubMed ID: 30663978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spanish Menopause Society position statement: Use of denosumab in postmenopausal women.
    Cano A; Silvan JM; Estévez A; Baró F; Villero J; Quereda F; Ferrer J; Mendoza N; Sánchez-Borrego R;
    Maturitas; 2014 Sep; 79(1):117-21. PubMed ID: 25042873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand.
    Pongchaiyakul C; Nanagara R; Songpatanasilp T; Unnanuntana A
    J Med Econ; 2020 Jul; 23(7):776-785. PubMed ID: 32063082
    [No Abstract]   [Full Text] [Related]  

  • 5. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis.
    Popp AW; Varathan N; Buffat H; Senn C; Perrelet R; Lippuner K
    Calcif Tissue Int; 2018 Jul; 103(1):50-54. PubMed ID: 29380013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
    Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
    Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
    Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
    Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The sequential therapy of romosozumab followed by denosumab for osteoporosis.].
    Ono K; Tanaka S
    Clin Calcium; 2019; 29(3):357-362. PubMed ID: 30814382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management after first-line antiresorptive treatment for postmenopausal osteoporosis.
    Paccou J
    Joint Bone Spine; 2016 Jul; 83(4):373-5. PubMed ID: 26992951
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [How to manage the rebound effect at denosumab discontinuation and avoid multiple vertebral fractures?].
    Gonzalez Rodriguez E; Lamy O; Aubry-Rozier B; Stoll D; Uebelhart B
    Rev Med Suisse; 2019 Apr; 15(647):831-835. PubMed ID: 30994986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
    Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple vertebral fractures after denosumab discontinuation].
    Tjelum L; Eiken P
    Ugeskr Laeger; 2018 Nov; 180(45):. PubMed ID: 30404716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
    Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observations following discontinuation of long-term denosumab therapy.
    McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
    Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
    Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
    Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.